Ten years after being fired for taking a mental health leave after the Virginia Tech massacre, I was diagnosed as "schizophrenic" and involuntarily committed to a hospital. Now I have a job and a life, but I'm still forced to take drugs and report to a social worker.
Gottstein’s book is The Pentagon Papers of the traditional mental health system, because he exposes a mind-blowing number and variety of cold-blooded, calculating actions on the part of Eli Lilly in trying to hide what it knew to be the devastating effects of its hugely profitable Zyprexa.
While most of the sting is gone, even now — almost sixty years on — I can’t get through a single day without thinking about shock treatment and the state hospital. I regularly have dreams or nightmares about being lost in a strange place and someone making me feel like dirt.
A new study finds that clinicians’ disregard for mental health patients’ insight into their own condition may be detrimental to treatment.
Antipsychotic drugs are prescribed on the basis of trials that demonstrate a higher rate of ‘relapse’ in people who are withdrawn from these drugs compared to those who continue to take them. Yet, incredibly, there is no consensus about what ‘relapse’ means in this situation.
A new special issue brings together articles exploring the harmful effects of simultaneous multiple medication use.
During a period of self-doubt, I chose to see a psychiatrist because I was engulfed in negative thoughts and couldn't find a direction in life. The slightest joys came only when I was high. Though my weed addiction was likely causing all of my symptoms, my psychiatrist’s response was to prescribe antipsychotics.
There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.
Increased Parkinson's risk could be related to lithium, antipsychotic, and antiepileptic drug use.
The National Council for Behavioral Health has released a new pamphlet titled “Guide to Long-Acting Medications for Providers and Organizations.” By downplaying some aspects of the available science, the pamphlet implicitly acts as a promotional tool for the pharmaceutical industry.
A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.
Researchers question biases of preliminary trials that found that sodium nitroprusside, an antihypertensive drug, has positive effects on schizophrenia symptoms.
Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.
A new study provides an insider’s look into how psychiatrists view the establishment of drug-free programs in Norway.
Twice as many teenagers with ADHD experienced severe psychosis when taking Adderall, as compared to Ritalin, according to a new study.
A new study examines the effects of CBD as an adjunct therapy to antipsychotic medication for patients diagnosed with schizophrenia.
A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Mixed-Methods study explores the experiences of antipsychotic discontinuation among service users.
A recent paper published in Schizophrenia Bulletin reported on a meta-analysis of antipsychotic drugs which found that a significant number of people do not experience a remission of psychotic symptoms. The evidence base suggests that it is time for us to reappraise the effectiveness of these drugs and shift our practice patterns accordingly.
A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
Researchers review the risks and benefits of deprescribing from antipsychotic drugs and advocate for a patient-centered approach to tapering.